M. Pan

发表

Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway

K. Glaser, S. Davidsen, Z. Xie, 2008, Leukemia.

In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor.

Hanry Yu, Chonglei Bi, K. Glaser, 2008, Leukemia research.

Progressive loss of epidermal growth factor receptor in a subpopulation of breast cancers: implications in target-directed therapeutics

M. Salto‐Tellez, P. Tan, M. Hande, 2007, Molecular Cancer Therapeutics.

Expression of Wnt-5a and its clinicopathological significance in hepatocellular carcinoma.

Q. Rao, X. Liu, B. Wu, 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.